Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on MASSIMO ZANETTI BEVERAGE GRO. We currently have 1 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
MASSIMO ZANETTI BEVERAGE GRO
MASSIMO ZANETTI BEVERAGE GRO
Segafredo and regional brands drive growth
19 Sep 16
For Massimo Zanetti Beverage Group (MZBG), development of its global brand Segafredo goes hand in hand with its established regional brands such as San Marco and Kawai. Growing these, while investing in acquired brands such as Boncafè (Asia), Nutricafès (Portugal) and Meira (Finland), is central to strategy. Revenues are 90% outside Italy and the June 2015 IPO marked a commitment to global expansion. With double-digit earnings growth consensus forecast over 2016 and 2017, the journey is underway.
20 Apr 17
Although the last two months have seen a broadly neutral performance from the UK healthcare sector compared to a significantly more volatile 6 months prior, we continue to expect macro-events and increased geo-political risk to result in an overall neutral performance from the sector over the next period. However, company specific news is likely to drive a strong outperformance from selected mid-market companies. We retain our neutral sector stance whilst highlighting those we expect to outperform.
03 Apr 17
After much heralding, MIFID II is finally beginning to have an impact on the business of investment research, though its true ramifications might take years to be seen. The role of analyst research is widely misunderstood. It is not all about the conclusion: the rating and price target. The real content of research is about what is discounted in the current share price and what assumptions would produce different outcomes.
Small Cap Breakfast
23 Mar 17
K3 Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.
Positioned to perform
08 Mar 17
Stock Spirits (STCK LN, BUY, T/P 240p) preliminary 2016 results were in line with expectations, reconfirming their 11th January 2017 trading statement. Adjusted EBITDA was €51.5m compared with Bloomberg consensus and Whitman Howard estimates of €50.0m. The company are hosting an analyst presentation at 9.00am.
Undevilish detail implies more upside to come
09 Mar 17
While Stock Spirits (STCK LN, BUY, T/P 240p) appears in better shape than for some time, further improvements seem likely. Polish vodka market conditions remain competitive. But in our view attention to detail suggests the company is implementing the right brand strategy, appropriate pricing architecture and upgraded its sales function – hence, more upside to come. BUY